GOG 225: Progression-Free Survival (LIvES) Study

GOG 225: Progression-Free Survival (LIvES) Study

Share this:

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? (LIvES)

PROTOCOL ID

GOG225

PROTOCOL DESCRIPTION

This year alone 22,430 women will be diagnosed with ovarian cancer in the U.S. and one in 70 US women will be diagnosed with ovarian cancer in her lifetime. Finding new ways to reduce recurrent disease in ovarian cancer survivors is an important focus of current ovarian cancer research. Research suggests that maintaining a healthy lifestyle could reduce recurrent ovarian cancer risk.

Eligible participants will be randomly assigned to one of two groups: Usual Care Group or Lifestyle Intervention Group. Participants assigned to the lifestyle intervention group will be asked to modify their diet and physical activity levels while those assigned to the usual care group will be asked to go about their usual diet and exercise routine. They will be asked to fill out questionnaires, give a blood specimen, wear a pedometer, and participate in telephone coaching calls over a period of two years. Information obtained through completed questionnaires, etc. will be used to compare the two groups to see if diet and exercise impact the incidence of ovarian, fallopian tube and primary peritoneal cancer recurrence.

This study is being sponsored by the Gynecologic Oncology Group in partnership with the Arizona Cancer Center at the University of Arizona. It is open to eligible women nationwide and is currently being offered at Carilion Clinic's Gynecological Oncology office in Roanoke, Va.

ELIGIBILITY CRITERIA

Patients MUST:

  • Age 18 or older
  • Ovarion, Fallopian Tube or Primary Peritoneal cancer survivor with a history of stage II- IV
  • Completed cancer treatment within the past 6 weeks to 4 months
  • No clinical evidence of persistent or recurrent disease
  • No history of diet associated disease ( renal, liver, etc.)
  • Willing to fill out study questionnaires and complete telephone coaching during the study.

Primary Investigator(s)

Janet L. Osborne, M.D.

Contact Information

Sarah Henderson
Clinical Research Coordinator
Phone: 540-581-0160
Email: sehenderson@carilionclinic.org